These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 34343944)

  • 1. 'Synthetic cannabis': A dangerous misnomer.
    Darke S; Banister S; Farrell M; Duflou J; Lappin J
    Int J Drug Policy; 2021 Dec; 98():103396. PubMed ID: 34343944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabis adulterated with the synthetic cannabinoid receptor agonist MDMB-4en-PINACA and the role of European drug checking services.
    Oomen PE; Schori D; Tögel-Lins K; Acreman D; Chenorhokian S; Luf A; Karden A; Paulos C; Fornero E; Gerace E; Koning RPJ; Galindo L; Smit-Rigter LA; Measham F; Ventura M
    Int J Drug Policy; 2022 Feb; 100():103493. PubMed ID: 34687992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects.
    van Amsterdam J; Brunt T; van den Brink W
    J Psychopharmacol; 2015 Mar; 29(3):254-63. PubMed ID: 25586398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Intoxications with synthetic cannabinoids].
    Zanen JG; Leegwater E; Schippers EF; Wilms EB
    Ned Tijdschr Geneeskd; 2023 Mar; 167():. PubMed ID: 36943159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Intoxications with synthetic cannabinoids].
    Zanen JG; Leegwater E; Schippers EF; Wilms EB
    Ned Tijdschr Geneeskd; 2023 Feb; 166():. PubMed ID: 36752668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does cannabis testing in the military drive synthetic cannabinoid use? Self-reported use motivations among justice-involved veterans.
    Santangelo O; Baldwin JM; Stogner J
    Int J Drug Policy; 2022 Aug; 106():103756. PubMed ID: 35738030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How should policymakers regulate the tetrahydrocannabinol content of cannabis products in a legal market?
    Hall W; Leung J; Carlini BH
    Addiction; 2023 Jun; 118(6):998-1003. PubMed ID: 36662648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis.
    Craft S; Ferris JA; Barratt MJ; Maier LJ; Lynskey MT; Winstock AR; Freeman TP
    Psychopharmacology (Berl); 2022 May; 239(5):1349-1357. PubMed ID: 34533608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can cannabis kill? Characteristics of deaths following cannabis use in England (1998-2020).
    Rock KL; Englund A; Morley S; Rice K; Copeland CS
    J Psychopharmacol; 2022 Dec; 36(12):1362-1370. PubMed ID: 35946604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delta-8, Delta-10, HHC, THC-O, THCP, and THCV: What Should We Call These Products?
    Rossheim ME; LoParco CR; Henry D; Trangenstein PJ; Walters ST
    J Stud Alcohol Drugs; 2023 May; 84(3):357-360. PubMed ID: 36971760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A naturalistic study of orally administered vs. inhaled legal market cannabis: cannabinoids exposure, intoxication, and impairment.
    Bidwell LC; Karoly HC; Torres MO; Master A; Bryan AD; Hutchison KE
    Psychopharmacology (Berl); 2022 Feb; 239(2):385-397. PubMed ID: 34708254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consumer Experiences with Delta-8-THC: Medical Use, Pharmaceutical Substitution, and Comparisons with Delta-9-THC.
    Kruger DJ; Kruger JS
    Cannabis Cannabinoid Res; 2023 Feb; 8(1):166-173. PubMed ID: 34797727
    [No Abstract]   [Full Text] [Related]  

  • 13. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?
    Fantegrossi WE; Moran JH; Radominska-Pandya A; Prather PL
    Life Sci; 2014 Feb; 97(1):45-54. PubMed ID: 24084047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists.
    Patel M; Manning JJ; Finlay DB; Javitch JA; Banister SD; Grimsey NL; Glass M
    Biochem Pharmacol; 2020 May; 175():113871. PubMed ID: 32088263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fourth Generation of Synthetic Cannabinoid Receptor Agonists: A Review on the Latest Insights.
    Malaca S; Busardò FP; Nittari G; Sirignano A; Ricci G
    Curr Pharm Des; 2022; 28(32):2603-2617. PubMed ID: 34781870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins.
    Banister SD; Connor M
    Handb Exp Pharmacol; 2018; 252():165-190. PubMed ID: 29980914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protocol for a mobile laboratory study of co-administration of cannabis concentrates with a standard alcohol dose in humans.
    Karoly HC; Prince MA; Emery NN; Smith EE; Piercey CJ; Conner BT
    PLoS One; 2022; 17(11):e0277123. PubMed ID: 36327298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies.
    De Aquino JP; Bahji A; Gómez O; Sofuoglu M
    Drug Alcohol Depend; 2022 Dec; 241():109702. PubMed ID: 36434879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabis Exposure Decreases Need for Blood Pressure Support During General Anesthesia in Orthopedic Trauma Surgery.
    Yeung BG; Ma MW; Scolaro JA; Nelson AM
    Cannabis Cannabinoid Res; 2022 Jun; 7(3):328-335. PubMed ID: 34227872
    [No Abstract]   [Full Text] [Related]  

  • 20. On the duration of cannabis effects and the presence of THC in the body.
    Mørland J; Bretteville-Jensen AL; Bramness JG
    Addiction; 2023 Feb; 118(2):390-391. PubMed ID: 36331427
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.